Phytochemical, Toxicological and Pharmacological Studies of Asiasari Radix et Rhizoma: A Review
Abstract
Herba Asari and Asiasari Radix (AR) have a centuries-old history as a folk medicine in China, Korea and Japan. AR has long been used in combination with other herbs to treat cough, toothache, headache, neuralgia, aphthous stomatitis, gingivitis, chronic bronchitis, asthma and allergies. AR from three species of the genus Asarum: A. heterotropoides Fr. Schmidt var. mandshuricum (Maxim.) Kitag., A. sieboldii Miq. var. seoulense Nakai and A. sieboldii Miq are recognized as original “Asiasari Radix et Rhizoma”. These species do not contain aristolochic acids (nephrotoxins present in the Asarum species) and therefore the roots of AR are recommended for use. Asiasari Radix is rich in volatile oils, phenylpropanoids, terpenoids, flavonoids, glycosides and lignins. The reported toxicological and pharmacological activities of AR, including antifungal, antimicrobial, antilisterial, antiallergic, acarcidal, larvicidal, anti-caries, anti-inflammatory, hepatoprotective, neuroprotective, cytotoxic and anticancer activities suggest its therapeutic potentials in drug discovery.
Keywords: Asarum; Asiasarum, Asiasarum heterotropoides var. mandshuricum, Asiasarum sieboldiiHerba Asari, Folk medicine, Pharmacological, Toxicological
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
